Methohexital

Methohexital
Skeletal formula
Ball-and-stick model
Systematic (IUPAC) name
5-hex-3-yn-2-yl-1- methyl-5-prop-2-enyl-1, 3-diazinane-2,4,6-trione
Clinical data
AHFS/Drugs.com Consumer Drug Information
Pregnancy
category
Routes of
administration		 Intravenous, rectal
Legal status
Legal status
  • AU: S4 (Prescription only)
  • Schedule IV
Pharmacokinetic data
Bioavailability I.V. ~100%
Rectal ~17%
Metabolism Hepatic
Biological half-life 5.6 ± 2.7 minutes
Excretion ?
Identifiers
CAS Number 151-83-7 YesY
ATC code N01AF01 (WHO) N05CA15 (WHO)
PubChem CID 9034
IUPHAR/BPS 7233
DrugBank DB00474 YesY
ChemSpider 8683 YesY
UNII E5B8ND5IPE YesY
KEGG D04985 YesY
ChEBI CHEBI:102216 YesY
ChEMBL CHEMBL7413 YesY
Chemical data
Formula C14H18N2O3
Molar mass 262.304
  (verify)

Methohexital or methohexitone (marketed under the brand name Brevital) is a drug which is a barbiturate derivative. It is classified as short-acting, and has a rapid onset of action. It is similar in its effects to sodium thiopental, a drug with which it competed in the market for anaesthetics.

Pharmacology

Methohexital binds to a distinct site which is associated with Cl− ionophores at GABAA receptors.[1] This increases the length of time which the Cl− ionopores are open, thus causing an inhibitory effect.

Metabolism of methohexital is primarily hepatic (i.e., taking place in the liver) via demethylation and oxidation. Side-chain oxidation is the primary means of metabolism involved in the termination of the drug's biological activity.

Protein binding is approximately 73% for methohexital.

Indications

Methohexital is primarily used to induce anesthesia, and is generally provided as a sodium salt (i.e. methohexital sodium). It is only used in hospital or similar settings, under strict supervision. It has been commonly used to induce deep sedation or general anesthesia for surgery and dental procedures. Unlike many other barbiturates, Methohexital actually lowers the seizure threshold, a property that make it particularly useful when anesthesia is provided for a electroconvulsive therapy (ECT). And rapid recovery rate with consciousness being gained within three to seven minutes after induction and full recovery within 30 minutes is a major advantage over other ECT barbiturates (Schulgasser and Borowitz 1963).

Synthesis

Methohexital, 5-allyl-1-methyl-5-(1-methyl-2-pentinyl barbituric acid, is synthesized in the classic manner of making barbituric acid derivatives, in particular by the reaction of malonic ester derivatives with derivatives of urea.

Methohexital synthesis: W.J. Doran, U.S. Patent 2,872,448 (1959).

The resulting allyl-(1-methyl-2-pentynyl) malonic ester is synthesized by subsequent alkylation of the malonic ester itself, beginning with 2-bromo-3-hexyne, which gives (1-methyl-2-pentynyl)malonic ester, and then by allylbromide. In the final step, reaction of the disubstituted malonic ester with N-methylurea gives desired methohexital.

References

  1. ↑ Katzung, Bertram G., Basic and Clinical Pharmacology, 10th ed., p. 406-407

[1]

External links

Wikimedia Commons has media related to Methohexital.


  1. ↑ SCHULGASSER, H; BOROWITZ, A (1963). "Methohexital anaesthesia in electroconvulsive therapy". South African Medical Journal 37: 870.
This article is issued from Wikipedia - version of the Thursday, April 14, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.